Overview

A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

Status:
Recruiting
Trial end date:
2028-07-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.
Phase:
Phase 1
Details
Lead Sponsor:
Johnson & Johnson Enterprise Innovation Inc.